RxDoctor Payments Data

Patrick Litster, PA

Physician Assistant · Hot Springs, ARNPI 1255369666

Payments from drug & device makers

$564in general payments, 2019–2025

Across 24 payments — averaging $23.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$193
  • Lilly USA, LLC$99
  • Otsuka America Pharmaceutical, Inc.$67
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$56
  • AbbVie$48
  • Boston Scientific$30
  • plus $71 from 4 others

What the payments were for

  • Food & beverage$564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$564 in reported general payments places this provider in the 55th percentile of 451 physician assistant providers in Arkansas.

See all physician assistant providers in Arkansas

Medicare billing

Part B allowed, 2024
$17,822
Medicare patients
220
Services billed
1,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol60$40,204
TrulicityDulaglutide36$37,821
JardianceEmpagliflozin46$36,655
OzempicSemaglutide35$32,911
EliquisApixaban35$31,539
MounjaroTirzepatide29$30,796
JanuviaSitagliptin Phosphate27$25,410
XareltoRivaroxaban29$23,609
RexultiBrexpiprazole15$21,843
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$20,673
Spiriva HandihalerTiotropium Bromide12$10,301
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,910
LinzessLinaclotide12$6,176
SymbicortBudesonide/Formoterol Fumarate12$5,090
Gabapentin330$4,839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$99$68,61765 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$193$52,20483 claims
Novo NordiskOzempic$16$32,91135 claims
MerckJanuvia, Dulera$21$29,66839 claims
Otsuka America Pharmaceutical, Inc.Rexulti$67$21,84315 claims
AbbVieLinzess$48$6,17612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 451 physician assistant providers in Arkansas.

Other physician assistant in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →